clinical trial · NCT04081350
A Study of LY3471851 in Participants With Eczema
Dermatitis, AtopicLY3471851Placebo
brief summary
The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with eczema. The study will last up to 48 weeks and may include up to 23 visits to the study center.
started
Dec 4, 2019
primary completion
Jun 24, 2022
completion
Jun 24, 2022
last updated
Feb 20, 2024
official title
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol